Welcome to our dedicated page for Sintx Technologies news (Ticker: SINT), a resource for investors and traders seeking the latest updates and insights on Sintx Technologies stock.
SINTX Technologies, Inc. develops and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. Company news centers on its advanced ceramics platform, FDA-cleared SINAPTIC® Foot & Ankle Osteotomy Wedge System, OsseoSculpt™ biologic, and SiNERGY™ silicon nitride/PEEK composite materials for patient-specific implant applications.
Recurring updates also cover commercialization milestones, first-in-human use of SINTX implants, strategic supply and private-label agreements, patent activity in antipathogenic materials, capital actions, operating efficiencies, and management or board changes. The company’s updates frame its current focus around medical-device applications, orthopedic and spine markets, U.S.-based manufacturing, and partnerships that extend the use of silicon nitride biomaterials.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
SINTX Technologies has completed renovations and equipment installation at its SINTX Armor facility in Salt Lake City, enhancing its capacity to manufacture high-performance ceramic armor products for personnel, aircraft, and vehicles. This facility spans 10,000 square feet and produces advanced materials like BoroShock and DuraShock, which offer lightweight, high-strength protection against projectiles. Following a strategic acquisition of B4C LLC, SINTX Armor anticipates a strong order book in 2023, aligning with a projected global ceramic armor market growth to USD $3.5 billion by 2027.
Summary not available.
SINTX Technologies, Inc. (NASDAQ: SINT) has announced a public offering of 2,150,000 units, priced at $5.60 each. Each unit consists of one share of common stock or one pre-funded warrant, along with one Class C Warrant and half of one Class D Warrant. The offering is expected to yield approximately $12 million in gross proceeds before expenses and is anticipated to close on February 10, 2023. The securities are offered under SEC regulations, and Maxim Group LLC is serving as the placement agent. SINTX focuses on advanced ceramics, particularly silicon nitride, for medical applications and has a history of product implantation since 2008.
SINTX Technologies reported preliminary unaudited financial results for Q4 2022 and the full year, highlighting a revenue of approximately $770k in Q4 and $1.6 million for the year. This marks a consistent quarter-on-quarter growth, surpassing previous annual revenues since selling its spine business in 2018. Government contracts contributed $521k in Q4 and $962k for the year, while commercial revenue from aerospace, energy, dental, and spine sectors reached $248k in Q4 and $602k annually. The company expects growth in 2023 and anticipates the Armor facility in Salt Lake City to be operational by Q1.
SINTX Technologies (NASDAQ: SINT) has announced it has regained compliance with NASDAQ's minimum bid price requirements. The company confirmed that its common stock closed at $1.00 or more per share for ten consecutive business days, from December 20, 2022, to January 4, 2023. This compliance with Listing Rule 5550(a)(2) means the previous issue is now resolved. SINTX is known for developing advanced ceramics for medical and technical applications, and its products have been in human use since 2008.
SINTX Technologies has secured a Phase I contract worth $150K from the U.S. Missile Defense Agency to enhance electrochemical machining (ECM) for aerospace components. This project focuses on developing corrosion-resistant, dielectric coatings aimed at extending tool life and reducing machining costs. Collaborating with Voxel Innovations, SINTX plans to scale up this technology for prototype development after successful contract completion. The U.S. micromachining market is growing, projected at $2.5 billion in 2019, with the non-traditional machining segment, including ECM, leading market advances.